PMID- 29781361 OWN - NLM STAT- MEDLINE DCOM- 20190107 LR - 20190107 IS - 1753-4666 (Electronic) IS - 1753-4658 (Print) IS - 1753-4658 (Linking) VI - 12 DP - 2018 Jan-Dec TI - Erythromycin combined with corticosteroid reduced inflammation and modified trauma-induced tracheal stenosis in a rabbit model. PG - 1753466618773707 LID - 10.1177/1753466618773707 [doi] LID - 1753466618773707 AB - BACKGROUND: Patients with endotracheal intubation or tracheostomy are subject to benign tracheal stenosis (TS), for which current therapies are unsatisfactory. We conducted a preliminary investigation of drugs and drug combinations for the prevention and treatment of TS in a rabbit model. METHODS: Fifty-four rabbits were apportioned into nine groups according to treatment: sham-operated control; untreated TS model; amikacin; budesonide; erythromycin; penicillin; amikacin + budesonide; erythromycin + budesonide; and penicillin + budesonide. TS was induced by abrasion during surgery. The drugs were applied for 7 days before and 10 days after the surgery. Rabbits were killed on the eleventh day. Tracheal specimens were processed for determining alterations in the thicknesses of tracheal epithelium and lamina propria via hematoxylin and eosin. The tracheal mRNA (assessed by real-time quantitative polymerase chain reaction) expressions of the following fibrotic-related factors were determined: transforming growth factor-beta1 (TGF- beta1), collagen type I (COL1A1), collagen type III (COL3A1), and interleukin-17 (IL-17). The protein levels of TGF-beta1, COL1A1, and COL3A1 were determined through immunohistochemistry and integrated optical densities. RESULTS: Compared with all other groups, the untreated TS model had significantly thicker tracheal epithelium and lamina propria, and higher mRNA and protein levels of all targeted fibrotic factors. The mRNA and protein levels of the targeted fibrotic factors in all the drug-treated groups were lower than those of the untreated TS model, and differences were most significant in the erythromycin + budesonide group. CONCLUSIONS: Erythromycin combined with budesonide may reduce inflammation and modify fibrosis progression in TS after tracheal injury. FAU - Enyuan, Qin AU - Enyuan Q AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Mingpeng, Xu AU - Mingpeng X AD - Fourth People's Hospital of Nanning, Nanning, China. FAU - Luoman, Gan AU - Luoman G AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Jinghua, Gan AU - Jinghua G AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Yu, Li AU - Yu L AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Wentao, Li AU - Wentao L AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Changchun, Hou AU - Changchun H AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Lihua, Li AU - Lihua L AD - Department of Respiratory Medicine, Fourth Affiliated Hospital of Guangxi Medical University, Liuzhou, China. FAU - Xiaoyan, Meng AU - Xiaoyan M AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Lei, Zhou AU - Lei Z AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, China. FAU - Guangnan, Liu AU - Guangnan L AD - Department of Respiratory Medicine, Second Affiliated Hospital of Guangxi Medical University, Nanning, 530007, China. LA - eng PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - England TA - Ther Adv Respir Dis JT - Therapeutic advances in respiratory disease JID - 101316317 RN - 0 (Anti-Bacterial Agents) RN - 0 (Anti-Inflammatory Agents) RN - 0 (Collagen Type I) RN - 0 (Collagen Type III) RN - 0 (Glucocorticoids) RN - 0 (Penicillins) RN - 0 (Transforming Growth Factor beta1) RN - 51333-22-3 (Budesonide) RN - 63937KV33D (Erythromycin) RN - 84319SGC3C (Amikacin) SB - IM MH - Amikacin/pharmacology MH - Animals MH - Anti-Bacterial Agents/*pharmacology MH - Anti-Inflammatory Agents/*pharmacology MH - Budesonide/*pharmacology MH - Collagen Type I/genetics/metabolism MH - Collagen Type III/genetics/metabolism MH - Disease Models, Animal MH - Drug Therapy, Combination MH - Erythromycin/*pharmacology MH - Fibrosis MH - Gene Expression Regulation MH - Glucocorticoids/*pharmacology MH - Male MH - Penicillins/pharmacology MH - Rabbits MH - Trachea/*drug effects/injuries/metabolism/pathology MH - Tracheal Stenosis/*drug therapy/etiology/metabolism/pathology MH - Transforming Growth Factor beta1/genetics/metabolism PMC - PMC5966843 OTO - NOTNLM OT - corticosteroid OT - erythromycin OT - fibrosis OT - intubation OT - tracheal stenosis OT - tracheostomy COIS- Conflict of interest statement: The authors declare that there is no conflict of interest. EDAT- 2018/05/22 06:00 MHDA- 2019/01/08 06:00 PMCR- 2018/05/20 CRDT- 2018/05/22 06:00 PHST- 2018/05/22 06:00 [entrez] PHST- 2018/05/22 06:00 [pubmed] PHST- 2019/01/08 06:00 [medline] PHST- 2018/05/20 00:00 [pmc-release] AID - 10.1177_1753466618773707 [pii] AID - 10.1177/1753466618773707 [doi] PST - ppublish SO - Ther Adv Respir Dis. 2018 Jan-Dec;12:1753466618773707. doi: 10.1177/1753466618773707.